Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting recent results from its WEIGHT-A24-1 animal study. A recent article notes that interim results, which are based on the first 28 days of dosing, are “noteworthy,” including all animals showing either a noticeable decrease in the rate of body weight gain or the beginning of weight reduction. According to the article, the study was designed to the impact of Lexaria’s patented DehydraTECH technology on glucagon-like peptide-1 (“GLP-1”) drugs for the potential treatment of diabetes and weight loss; the article noted that this study marks a “significant milestone” for the company because it is the first time Lexaria has used liraglutide in any of its GLP-1 studies.
To view the full article, visit https://cnw.fm/dK1bd
About Lexaria Bioscience Corp.
Lexaria Bioscience’s patented drug-delivery formulation and processing platform technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at http://cnw.fm/LXX
About CanadianCannabisWire
CanadianCannabisWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the Canadian cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CanadianCannabisWire, text “CCWIRE” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CanadianCannabisWire.com
Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: www.CanadianCannabisWire.com/Disclaimer
CanadianCannabisWire
Toronto, ON
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com
CanadianCannabisWire is powered by IBN
